New Drug Approval

The U.S. Food and Drug Administration (FDA) has approved for the first time a drug to treat the hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). The drug, Nuplazid (pimavanserin), produced by Acadia Pharmaceuticals, had been designated a Breakthrough…

Read More

Lack of Sleep effects Parkinson’s

Chronic lack of sleep and irregular sleep-wake cycles may be risk factors of Parkinson's disease, new work by researchers at the Lewis Katz School of Medicine at Temple University (LKSOM) suggests. In an animal model, the researchers show that disturbances…

Read More
Parkinson Writing

Writegen System gives back writing ability

European Parkinson Therapy Centre EuPaTh in collaboration with Oxford Brookes University has developed the Writegen therapy system to help people with Parkinson learn to write again. Using Neuroplastic techniques and a unique system that tricks the mind into writing better.…

Read More

New technique offers new way forward

For decades, the elusive holy grail in Parkinson's disease research has been finding a way to repair faulty dopamine neurons and put them back into patients, where they will start producing dopamine again. Researchers have used foetal material, which is…

Read More
Neuroprotection

Neuroprotection breakthrough

A team of scientists at the University of Nebraska Medical Center (UNMC) and Longevity Biotech, Inc. demonstrated that neuroprotection could be attained in preclinical models by a novel drug candidate that changes immune responses. The results, published today in the…

Read More

real time measurements of dopamine

New York: Scientists have reported first-ever measurements of a key neurotransmitter involved in learning with unprecedented precision in the brains of people with Parkinson's disease. The measurements, collected during brain surgery as the conscious patients played an investment game, demonstrate…

Read More
Parkinson Centre

Inosine brings hope

Inosine trial secures phase III funding The Michael J. Fox Foundation’s largest grant to a single investigator thus far awarded $5.6M in 2008 to Michael Schwarzschild, PhD, of Massachusetts General Hospital for a Phase II trial of inosine – a…

Read More

Xadago approved in Switzerland

The approval in Switzerland was preceded by the marketing authorization throughout the European Union by the Commission of the EU, in February 2015. Xadago was also accepted for review by the US FDA and has a current PDUFA date of…

Read More
Ricerca Parkinson

A new therapy for Parkinson?

Two University of Kentucky researchers will present evidence supporting a promising new therapy for Parkinson’s disease as part of a showcase of scientific research and innovation during the Michael J. Fox Foundation (MJFF) Parkinson’s Disease Therapeutics Conference. University of Kentucky…

Read More